ADT + abiraterone + prednisone (continuous)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-LEUPROLIDE` `DRUG-ABIRATERONE` `DRUG-PREDNISONE`

ID	`REG-ADT-ABIRATERONE`
Type	Regimen
Status	pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-PROSTATE-2024` `SRC-NCCN-PROSTATE-2025`

Notes

LATITUDE: ADT + abiraterone superior to ADT alone in high-risk mHSPC. COU-AA-302 / COU-AA-301: established in chemo-naive and post-chemo mCRPC. Always with prednisone — NEVER alone (mineralocorticoid syndrome). Cross-disease use: same regimen reused for mCRPC 1L and high-risk mHSPC.

Used By

Handbook Chapters

HB-PROSTATE-MCRPC-1L - Metastatic castration-resistant prostate cancer: biomarker and sequencing reasoning

Handbook Questions

HQ-PROSTATE-MCRPC-1L-001 - HQ-PROSTATE-MCRPC-1L-001

Indication

IND-PROSTATE-MHSPC-1L-ARPI-DOUBLET - IND-PROSTATE-MHSPC-1L-ARPI-DOUBLET